Skip to content

Surface coated commercially available contact lenses to control bacterial attachment to the contact lens surface during continuous wear modality.

Ex-vivo Antibacterial Activity of Melimine Attached Contact Lenses

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/02/031601
Enrollment
12
Registered
2021-02-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Surface coated commercially available Acuvue 2 contact lens with Melimine: Participants will wear the Melimine coated commercially available Acuvue 2 contact lens in one eye and commerc

Sponsors

Hyderabad Eye Research Foundation
Lead Sponsor
School of Optometry and Vision Science
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. Able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent. 2. Are 18 years to 40 years old 3. Willing to comply with the contact lens wear and visits as directed by the investigator 4. Have normal ocular health which would not prevent the participant from safely wearing contact lenses. 5. Require contact lens correction between -1.00 and -6.00D 6. Is correctable to at least 6/12 (20/40) or better in each eye with contact lenses/spectacles

Exclusion criteria

Exclusion criteria: 1. Any pre-existing ocular irritation, injury or condition (including keratoconus and herpes keratitis) of the cornea, 2. Conjunctiva or eyelids that would preclude contact lens fitting and safe wearing of contact lenses; 3. Any systemic disease that adversely affects ocular health e.g. diabetes, Gravesâ??s disease, and auto-immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjögrens syndrome and systemic lupus erythematosis. Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants; 4. An active corneal infection or any active ocular disease that would affect wearing of contact lenses; 5. Use of or a need for any therapeutic ocular medication at enrollment (that would be required to be discontinued during the study); 6. Use of or a need for any systemic medication or topical medications which may alter normal ocular findings, or are known to affect a participantâ??s ocular health or contact lens performance. 7. Have had eye surgery within 12 weeks immediately prior to enrollment for this trial; 8. Have any known allergy or intolerance to ingredients in any of the study products; 9. Currently enrolled in another clinical trial or participation in a clinical trial within the previous 2 weeks; 10. Be Pregnant or lactating (testing for pregnancy is not required. A participantâ??s verbal report is sufficient).

Design outcomes

Primary

MeasureTime frame
To determine if melimine coated commercially available hydrogel contact lenses can reduce the bacterial adhesion to the lens surface after different time period of lens wearTimepoint: 8 hours of lens wear, 1 night lens wear, 3 days, 6 days and 9 days lens wear

Secondary

MeasureTime frame
NoneTimepoint: Not Applicable

Countries

India

Contacts

Public ContactMs Charitha

L V Prasad Eye Institute

savitri@lvpei.org040-30612504

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026